Cargando…

Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China

BACKGROUND: Adverse drug reactions (ADRs) are a leading cause of morbidity in developed countries and represent a substantial burden on health-care resources. Many countries spent 15% to 20% of their hospital budgets to treat drug complications. However, few studies have measured the pharmacoeconomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Qing-ping, Shi, Xiao-dong, Jiang, Feng, Ding, Yan, Liu, Mei-ling, Yu, Jin-xiu, Zhu, Shu-qiang, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931293/
https://www.ncbi.nlm.nih.gov/pubmed/24533894
http://dx.doi.org/10.1186/1472-6963-14-73
_version_ 1782304638937071616
author Qing-ping, Shi
Xiao-dong, Jiang
Feng, Ding
Yan, Liu
Mei-ling, Yu
Jin-xiu, Zhu
Shu-qiang, Zhang
author_facet Qing-ping, Shi
Xiao-dong, Jiang
Feng, Ding
Yan, Liu
Mei-ling, Yu
Jin-xiu, Zhu
Shu-qiang, Zhang
author_sort Qing-ping, Shi
collection PubMed
description BACKGROUND: Adverse drug reactions (ADRs) are a leading cause of morbidity in developed countries and represent a substantial burden on health-care resources. Many countries spent 15% to 20% of their hospital budgets to treat drug complications. However, few studies have measured the pharmacoeconomic effects of ADRs on hospitalized patients in China. The study estimates the costs of ADRs as identified from the spontaneous voluntary reports completed from healthcare professionals. To do so, we calculate these costs, determine the sum of Medicare payments and their proportion of total healthcare spending, and evaluate the incidence of ADRs, characteristics of hospitalized ADR patients, and outcomes of ADRs in China. METHODS: This retrospective survey studied patients who experienced ADRs during their hospitalization at a Chinese tertiary-care teaching hospital. The patients were divided into group A and group B according to general ADRs and serious ADRs in Provisions for Adverse Drug Reaction Monitoring and Reporting. The direct costs included treatment fees, inspection fees, laboratory fees, materials fees, bed charges, drug charges, nursing care, meals, and other expenses and the sunk-cost losses were calculated according to the hospital information system (HIS). Indirect costs of ADR treatment were calculated according to the human capital approach. The epidemiological characteristics of ADRs were evaluated. RESULTS: 2739 were diagnosed with ADR during the study period, which translates to an ADR rate of 0.81%. The total socioeconomic loss from 2739 cases of ADR was estimated at ¥817401.69, consisting of direct costs of ¥603252.81 and indirect costs of ¥214148.88. On average, the costs per patient amounted to ¥196.10 in group A, ¥7032.29 in group B. The sum of medicare payment and proportion were ¥219061.13 (65.23%) and ¥105422.02 (39.42%) in group A and B. The ADR incidence in old-age patients was significantly higher than in other age groups (P < 0.0001). The most common drug class associated with ADRs represented antibiotics (957 patients, 34.94%). CONCLUSIONS: The costs of especially severe ADRs could not be ignored, and in this hospital 0.13% of patients were diagnosed with ADRs associated with relatively higher direct costs than who suffered from mild ADRs, largely due to extended hospitalization.
format Online
Article
Text
id pubmed-3931293
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39312932014-02-22 Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China Qing-ping, Shi Xiao-dong, Jiang Feng, Ding Yan, Liu Mei-ling, Yu Jin-xiu, Zhu Shu-qiang, Zhang BMC Health Serv Res Research Article BACKGROUND: Adverse drug reactions (ADRs) are a leading cause of morbidity in developed countries and represent a substantial burden on health-care resources. Many countries spent 15% to 20% of their hospital budgets to treat drug complications. However, few studies have measured the pharmacoeconomic effects of ADRs on hospitalized patients in China. The study estimates the costs of ADRs as identified from the spontaneous voluntary reports completed from healthcare professionals. To do so, we calculate these costs, determine the sum of Medicare payments and their proportion of total healthcare spending, and evaluate the incidence of ADRs, characteristics of hospitalized ADR patients, and outcomes of ADRs in China. METHODS: This retrospective survey studied patients who experienced ADRs during their hospitalization at a Chinese tertiary-care teaching hospital. The patients were divided into group A and group B according to general ADRs and serious ADRs in Provisions for Adverse Drug Reaction Monitoring and Reporting. The direct costs included treatment fees, inspection fees, laboratory fees, materials fees, bed charges, drug charges, nursing care, meals, and other expenses and the sunk-cost losses were calculated according to the hospital information system (HIS). Indirect costs of ADR treatment were calculated according to the human capital approach. The epidemiological characteristics of ADRs were evaluated. RESULTS: 2739 were diagnosed with ADR during the study period, which translates to an ADR rate of 0.81%. The total socioeconomic loss from 2739 cases of ADR was estimated at ¥817401.69, consisting of direct costs of ¥603252.81 and indirect costs of ¥214148.88. On average, the costs per patient amounted to ¥196.10 in group A, ¥7032.29 in group B. The sum of medicare payment and proportion were ¥219061.13 (65.23%) and ¥105422.02 (39.42%) in group A and B. The ADR incidence in old-age patients was significantly higher than in other age groups (P < 0.0001). The most common drug class associated with ADRs represented antibiotics (957 patients, 34.94%). CONCLUSIONS: The costs of especially severe ADRs could not be ignored, and in this hospital 0.13% of patients were diagnosed with ADRs associated with relatively higher direct costs than who suffered from mild ADRs, largely due to extended hospitalization. BioMed Central 2014-02-17 /pmc/articles/PMC3931293/ /pubmed/24533894 http://dx.doi.org/10.1186/1472-6963-14-73 Text en Copyright © 2014 Qing-ping et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research Article
Qing-ping, Shi
Xiao-dong, Jiang
Feng, Ding
Yan, Liu
Mei-ling, Yu
Jin-xiu, Zhu
Shu-qiang, Zhang
Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title_full Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title_fullStr Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title_full_unstemmed Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title_short Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China
title_sort consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931293/
https://www.ncbi.nlm.nih.gov/pubmed/24533894
http://dx.doi.org/10.1186/1472-6963-14-73
work_keys_str_mv AT qingpingshi consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT xiaodongjiang consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT fengding consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT yanliu consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT meilingyu consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT jinxiuzhu consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina
AT shuqiangzhang consequencesmeasurementandevaluationofthecostsassociatedwithadversedrugreactionsamonghospitalizedpatientsinchina